This study is designed to investigate whether a potential new treatment is effective for treating hypoactive sexual desire disorder (low sexual desire) in women.
Hypoactive sexual desire dysfunction (HSDD) refers to low sexual desire with associated distress. HSDD can significantly affect one’s wellbeing, quality of life and partner relationships.
The current study aims to investigate a potential new treatment for HSDD.
The potential new treatment, referred to as BP101, has been shown to improve sexual function in women with decreased libido and has the potential to provide an effective treatment for HSDD.
Who is it for? Main eligibility criteria:
Meet the Criteria for a Diagnosis of HSDD
Pre-menopausal women between the ages of 21-50
In relationship for over 1 year
No diagnosis of any other sexual dysfunction disorder
Study details: This study will evaluate the effect of three different doses of BP101 administered daily on desire, compared with placebo. There is a 3:1 chance of being randomly selected to receive the BP101 compared to the placebo. Both the BP101 and placebo are administered via a nasal spray.
Overall, the study involves 5 clinic visits and 5 calls over a period of 4 months. During these visits, you will complete questionnaires and general examinations including vital sign measurements and a blood test.